Deal could be worth up to €545 million, including upfront and milestone payments, as well as low to mid-teen royalties based on future sales

该交易价值可能高达5.45亿欧元，包括预付款、里程碑付款以及基于未来销售额的低至中双位数比例的特许权使用费。

/PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study..

/PRNewswire/ -- 专注于加速药物开发的原生人工智能制药公司 Formation Bio 今日宣布，其子公司 Libertas Bio 已将口服双重 JAK/SYK 抑制剂 Gusacitinib 授权给赛诺菲。赛诺菲将通过一期临床研究探索其在一种此前未被研究过的新适应症中的潜力。

Gusacitinib was acquired by Formation Bio (formerly known as TrialSpark) in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next stage of development, with Sanofi leveraging its global expertise in drug development and commercialization to explore its potential in new indications..

2022 年末，Formation Bio（前身为 TrialSpark）从 Asana BioSciences 收购了 Gusacitinib，作为一系列研究性药物组合的一部分。此次与赛诺菲的交易使 Gusacitinib 进入了其发展的下一阶段，赛诺菲将利用其在全球药物开发和商业化方面的专业知识，探索其在新适应症中的潜力。

Formation Bio has licensed gusacitinib to Sanofi, who will explore its potential in a new indication.

Formation Bio 已将古沙替尼的许可授予赛诺菲，后者将探索其在新适应症中的潜力。

This transaction exemplifies Formation Bio's differentiated business model: identifying and acquiring high-potential clinical-stage assets. Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise.

这笔交易体现了 Formation Bio 的差异化商业模式：识别并收购高潜力的临床阶段资产。Formation Bio 与赛诺菲有着多项长期合作，专注于识别高潜力资产，并共同开发利用共享数据和技术专长的人工智能工具。

This latest transaction builds on that collaboration, further strengthening both companies' commitment to advancing promising therapies through innovative technology and scientific excellence..

这项最新的交易建立在此前的合作基础上，进一步加强了两家公司通过创新技术和科学卓越推动有前景的疗法的承诺。

Benjamine Liu, Co-Founder & CEO of Formation Bio, commented:

Benjamine Liu，Formation Bio的联合创始人兼首席执行官评论道：

'Formation Bio is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We're proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.'

“Formation Bio正在通过每个步骤的彻底效率重新定义药物开发。我们获取高潜力资产，迅速行动以释放价值，并在关键转折点与合作伙伴携手。我们为拥有赛诺菲作为世界级合作伙伴，共同加速医学创新而感到自豪。”

About Formation Bio

关于Formation Bio

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients.

Formation Bio是一家由人工智能驱动的制药公司，其特点是药物开发效率显著提升。Formation Bio构建了技术和人工智能平台、流程及能力，以加速药物开发和临床试验的各个方面。Formation Bio通过合作、收购或从制药公司和生物技术公司获得药物许可，利用其专有技术和人工智能能力，推动项目超越临床概念验证阶段并进一步发展，最终助力新药惠及患者。